Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Individualized dynamic risk assessment for multiple myeloma.
Murie C, Turkarslan S, Patel A, Coffey DG, Becker PS, Baliga NS. Murie C, et al. Among authors: becker ps. medRxiv [Preprint]. 2024 Apr 3:2024.04.01.24305024. doi: 10.1101/2024.04.01.24305024. medRxiv. 2024. PMID: 38633807 Free PMC article. Preprint.
Elucidation and Pharmacologic Targeting of Master Regulator Dependencies in Coexisting Diffuse Midline Glioma Subpopulations.
Fernández EC, Tomassoni L, Zhang X, Wang J, Obradovic A, Laise P, Griffin AT, Vlahos L, Minns HE, Morales DV, Simmons C, Gallitto M, Wei HJ, Martins TJ, Becker PS, Crawford JR, Tzaridis T, Wechsler-Reya RJ, Garvin J, Gartrell RD, Szalontay L, Zacharoulis S, Wu CC, Zhang Z, Califano A, Pavisic J. Fernández EC, et al. Among authors: becker ps. bioRxiv [Preprint]. 2024 Mar 17:2024.03.17.585370. doi: 10.1101/2024.03.17.585370. bioRxiv. 2024. PMID: 38559080 Free PMC article. Preprint.
TP53 Mutations are Associated with CD19 Negative Relapse and Inferior Outcomes after Blinatumomab in Adults with ALL.
Aldoss I, Li S, Zhang J, Clark MC, Agrawal V, Pourhassan H, Koller PB, Aribi A, Ali H, Blackmon A, Otoukesh S, Sandhu KS, Ball BJ, Arslan S, Artz AS, Amanam I, Al Malki MM, Salhotra A, Kovacsovics TJ, Murphy LA, Afkhami M, Ngo D, Tinajero J, Gu Z, Becker PS, Nakamura R, Stein AS, Marcucci G, Forman SJ, Pullarkat VA. Aldoss I, et al. Among authors: becker ps. Blood Adv. 2025 Jan 16:bloodadvances.2024014986. doi: 10.1182/bloodadvances.2024014986. Online ahead of print. Blood Adv. 2025. PMID: 39820649
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Aldoss I, Zhang J, Shimamoto K, Saygin C, Robbins M, Agrawal V, Aribi A, Karaoglu DA, Pourhassan H, Koller P, Ali H, Blackmon A, Otoukesh S, Sandhu K, Ball B, Artz AS, Al Malki MM, Salhotra A, Tinajero J, Gu Z, Lagman I, Velasquez M, Dang J, Becker PS, Afkhami M, Ghoda L, Stock W, Forman SJ, Stein A, Marcucci G, Pullarkat V. Aldoss I, et al. Among authors: becker ps. Haematologica. 2024 Nov 7. doi: 10.3324/haematol.2024.286427. Online ahead of print. Haematologica. 2024. PMID: 39506897 Free article.
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.
Kopmar NE, Othus M, Quach K, Rasmussen A, Schonhoff K, Becker PS, Walter RB, Halpern AB, Salit R, Cassaday RD, Shustov A, Stewart FM, Oehler VG, Scott BL, Sandmaier BM, Lee SJ, Estey EH, Percival MM. Kopmar NE, et al. Among authors: becker ps. Transplant Cell Ther. 2024 Jul;30(7):727.e1-727.e8. doi: 10.1016/j.jtct.2024.05.002. Epub 2024 May 5. Transplant Cell Ther. 2024. PMID: 38710302
Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia.
Qin G, Dai J, Chien S, Martins TJ, Loera B, Nguyen QH, Oakes ML, Tercan B, Aguilar B, Hagen L, McCune J, Gelinas R, Monnat RJ Jr, Shmulevich I, Becker PS. Qin G, et al. Among authors: becker ps. Clin Cancer Res. 2024 Jun 14;30(12):2659-2671. doi: 10.1158/1078-0432.CCR-23-1674. Clin Cancer Res. 2024. PMID: 38619278 Free PMC article.
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP, Ridinger M, Becker PS, Lin TL, Silberman SL, Wang ES, Zeidan AM. Croucher PJP, et al. Among authors: becker ps. Ann Hematol. 2023 Nov;102(11):3049-3059. doi: 10.1007/s00277-023-05442-9. Epub 2023 Sep 13. Ann Hematol. 2023. PMID: 37702821 Free PMC article. Clinical Trial.
188 results